Authors
Latest:
Staging System for HPV-Related Oropharynx Cancer Paves Way for ChangeA new staging system for head and neck cancers recognizes that patients with oropharyngeal malignancies associated with the human papillomavirus often have an excellent prognosis, but efforts to deintensify therapy for this population based on a fresh understanding of favorable risk factors may be premature.
Latest:
Radiotherapy in the Modern Era in the Management of Langerhans Cell HistiocytosisIntensity-modulated radiotherapy reduces the mean radiation dose delivered to critical normal structures and should be considered in Langerhans cell histiocytosis treatment when radiotherapy is indicated, particularly given the expected, long-term survival of these patients.
Latest:
Dr. Cerfolio on the Importance of Specialized Care in Lung CancerRobert J. Cerfolio, MD, director of the Lung Cancer Center, chief of clinical thoracic surgery, NYU Langone’s Perlmutter Cancer Center, discusses the importance of specialized care in lung cancer and sheds light on the current outlook of the disease.
Latest:
Dr. Cerfolio on Minimally Invasive Surgery in NSCLCRobert J. Cerfolio, MD, MBA, director, Lung Cancer Center, chief, clinical thoracic surgery, discusses the impact of minimally invasive surgery in the management of non–small cell lung cancer.
Latest:
Dr. Kreitman on Ongoing Research With Moxetumomab Pasudotox in Hairy Cell LeukemiaRobert J. Kreitman, MD, senior investigator and head of the Clinical Immunotherapy Section in the Laboratory of Molecular Biology at the National Cancer Institute, discusses ongoing research with moxetumomab pasudotox-tdfk (Lumoxiti) in patients with hairy cell leukemia (HCL).
Latest:
Covering Your Assets: Tailoring Your Asset Protection Plan to Your Career StageThe type of asset protection planning you need depends on where you are in your career.
Latest:
Gimme Shelter: Are Financial Safe Havens Truly Safe Anymore?The largest US financial institutions are on government life support.
Latest:
Future Perspectives in the Treatment of Advanced RCCOncologists discuss the need for more data on treatment duration in advanced RCC, emphasize the value of long-term patient follow-ups, and highlight the translational focus of the KCRS annual meeting, which combines clinical and early-stage research for renal cell carcinoma.
Latest:
Robert Korngold on Advances in Bone Marrow TransplantRobert Korngold, PhD, John Theurer Cancer Center looks back on the advances we've made so far in bone marrow transplant.
Latest:
Dr. Coleman on the FDA Approval of Tisotumab Vedotin in Recurrent or Metastatic Cervical CancerRobert L. Coleman, MD, FACOG, FACS, discusses the FDA approval of tisotumab vedotin in recurrent or metastatic cervical cancer.
Latest:
Future Outlook of Advanced Ovarian Cancer TreatmentComprehensive insights on unmet needs, ongoing research, and the future of advanced ovarian cancer treatment.
Latest:
Dr. Ferris on the Safety Profile of Transoral Robotic Surgical Resection in Oropharynx CancerRobert L. Ferris, MD, PhD, discusses the safety profile of transoral robotic surgical resection in oropharynx cancer.
Latest:
Dr. Fine on GTX in Inoperable Pancreatic CancerRobert L. Fine, MD, an associate professor of Medicine at New York Presbyterian Hospital-Columbia University Medical Center, discusses a phase II study that evaluated the efficacy of neoadjuvant gemcitabine, docetaxel, and capecitabine (GTX) in patients with inoperable pancreatic adenocarcinoma
Latest:
Dr. Kirkman on the Novel HER2-Specific Inhibitor ONT-380 for Breast CancerRobert L. Kirkman, MD, President and CEO, Oncothyreon, discusses the evaluation of ONT-380, an oral HER2-specific inhibitor, for the treatment of patents with HER2-positive metastatic breast cancer.
Latest:
Dr. Redner on the Activity of Venetoclax in AMLRobert L. Redner, MD, a medical oncologist and hematologist, and professor of medicine, at the University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, discusses the activity of venetoclax (Venclexta) in acute myeloid leukemia (AML).
Latest:
Dr. Talley on Clinical Trials for Patients With Chronic LeukemiasRobert L. Talley, MD, hematologist/medical oncologist, Centerpoint Medical Center, Sarah Cannon Cancer Institute, discusses clinical trials for patients with chronic leukemias.
Latest:
Robert Laszewski on the Effect of ACA on Urology PracticesRobert Laszewski, President, Health Policy and Strategy Associates, LLC, discusses the effects of the Affordable Care Act (ACA) on urology practices.
